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Abstract 
Colorectal cancer (CRC) is the second leading cause of cancer-related death. The prevalence of colorectal neoplasm is increasing. Many 
studies have shown that thyroid dysfunction may be connected with the higher risk of pancreatic and breast cancer, but only a few de-
scribed the role of thyroid dysfunction and thyroid hormone (TH) replacement in the development and risk of CRC. The aim of this study 
is to summarise all findings and potentially elucidate the connection between TH imbalance and colorectal cancer.
The systematic review was conducted according to PICO and PRISMA guidelines. We searched MEDLINE, ClinicalTrials.gov, www.clini-
caltrialsregister.eu, and Cochrane Library databases using the following keywords: “((((thyroid OR hypothyroidism OR hyperthyroidism 
OR levothyroxine OR hashimoto OR graves OR thyroidectomy)) AND (colon OR colorectal OR CRC)) NOT hashimoto[Author]) NOT 
graves[Author])”. No filters were used. 
Of total of 3054 articles identified by the search strategy, 11 met PICO criteria and were included into the review. Four of those were on 
cell lines and seven were human studies. Analysis of the included studies revealed an elevated risk of CRC in patients with hypothyroid-
ism with aORs ranging from 1.16 (95% CI: 1.08–1.24, p < 0.001) to 1.69 (95% CI: 1.21–2.36, p = 0.002). Moreover, TH replacement therapy 
has a protective effect for CRC risk with aOR ranging from 0.60 (95% CI: 0.44–0.81, p = 0.001) to 0.92 (95% CI: 0.86–0.98, p = 0.009). THs 
seem to play a role in colorectal carcinogenesis. Further studies are warranted to define the exact role of thyroid hormone imbalance in 
prevention and treatment of CRC. (Endokrynol Pol 2019; 70 (2): 190–197)
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Introduction 
According to the American Cancer Society colorectal 
cancer (CRC) is the third most common cancer diag-
nosed in both men and women (excluding skin cancers) 
and the third leading cause of cancer-related deaths 
worldwide [1]. Although the treatment of CRC has 
improved over the last few decades, it is still expected 
to cause about 8% of cancer-related deaths in 2018 [1]. 
The five-year relative survival rates for people with 
stage I CRC is approximately 92% [2]. However, it de-
creases to 12% for patients in stage IV of the disease [2]. 
Therefore, it is still crucial to explore the nature of CRC 
development, progression, and risk factors.
The majority of CRCs develop from adenomatous 
polyps arising from the intestinal lining. This phe-
nomenon is called adenoma-carcinoma sequence [3]. 
Numerous variables have been confirmed as risk fac-
tors of colorectal adenomas and CRC, such as obesity, 
physical inactivity, smoking, and low-fibre diet [4]. On 
the other hand, there are multiple agents showing 
a protective influence on risk of CRC. Widely used 
drugs like aspirin or metformin have already been 
found to have a preventive action against tumouri-
genesis of CRC [5, 6]. However, data on TH imbal-
ance and risk of CRC are still not comprehensively 
described. 
Thyroxine, the main product of thyroid gland (T4), 
is an inactive form of TH. Type 1 (D1) and 2 deiodinases 
(D2) convert it into T3, which is its active form. Both 
T3 and T4 can be transformed into inactive metabolites 
via type 3 deiodinase (D3) [7]. Deregulation of the D3 
function has been implicated in tumorigenesis of hae-
mangiomas, hepatocellular carcinomas, and breast and 
thyroid cancer [8–10].
Multiple studies have shown a significant connec-
tion between hypothyroidism and pancreatic, gastric, 
and breast cancer [11, 12]. The association between 
the dysfunction of thyroid gland and CRC was not 
investigated as fully. Therefore, the aim of this study 
is to perform a systematic review on the association 
between THs imbalance and CRC risk and treatment. 
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A systematic review
Search strategy and study acquisition 
This systematic review was performed according to 
PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) and PICO (Patients, In-
terventions, Comparisons, Outcomes) guidelines. On 
7th May 2018 the MEDLINE, ClinicalTrials.gov, www.
clinicaltrialsregister.eu, and Cochrane Library databases 
were searched. The following search query was used: 
“((((thyroid OR hypothyroidism OR hyperthyroidism 
OR levothyroxine OR hashimoto OR graves OR thy-
roidectomy)) AND (colon OR colorectal OR CRC)) NOT 
hashimoto[Author]) NOT graves[Author]”. No filters 
were active. Two independent researchers screened 
results. The initial search returned 3054 results. After 
screening of abstracts, 46 results were chosen for full 
text analysis, of which 11 met inclusion criteria and were 
included in the study. A flowchart of study inclusion is 
presented in Figure 1. 
Inclusion and exclusion criteria 
Studies were included into analysis if predefined PICO 
criteria were met (Tab. I). Articles were dichotomised 
Table I. PICO criteria used in the study 
Part A
PICO Description
Patients Cell studies:
Studies on colorectal cancer cell lines
And/or studies on colorectal cancer stem cells
Intervention Use of: T3, T4, or D3 inhibitors
Comparisons Cell lines exposed to change in thyroid hormone 
levels were compared to cell lines not exposed to 
such changes
Outcomes Rates of differentiation and proliferation
Part B
PICO Description
Patients Patients with diagnosed colorectal cancer
Patients with diagnosed thyroid diseases 
(subclinical hypothyroidism, hyperthyroidism)
Intervention –
Comparisons Patients exposed to higher or lower levels 
or thyroid hormones were compared  
to patients exposed to normal levels  
of thyroid hormones
Outcomes Colorectal cancer risk
Records identied through
database searching
(n = 3054)
Records after duplicates removed
(n = 3054)
Records screened
(n = 3054)
Full-text articles assessed
for eligibility
(n = 46)
Studies on cell lines
included
(n = 4)
Studies on humans
included
(n = 11)
Full-text articles excluded,
with reasons:
— did not meet PICO
— not in English (n = 35)
Records excluded
(n = 3008)
Additional records identied
through other sources
(n = 0)
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Figure 1. PRISMA protocol for data acquisition
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into two categories: cell-line studies (Tab. I, part A) and 
human studies (Tab. I, part B). 
Evidence extraction and synthesis
Information from studies that met eligibility criteria on 
cell lines was abstracted by two independent research-
ers into Table II. Information from studies that met 
eligibility criteria on humans was abstracted by two 
independent researchers into Table III.
Results
A total of 11 studies met predefined PICO criteria and 
were dichotomised into two categories: cell-line stud-
ies and human studies. No studies on animals were 
available. 
Cell lines studies 
A total of four studies were included into the review. 
Results are summarised in Table II. Included studies 
were based on varying methodology. One study was 
on CRC stem cells, and three studies were on CRC 
cells. Characteristics of included studies are summarised 
in Table II.
A study by Catalano et al. focused on the role of THs 
in CRC stem cell differentiation and their sensitivity 
to chemotherapy [13]. CRC stem cells (CR-CSC) are 
a small group of cells with self-renewing potential and 
the ability to induce tumour growth [14, 15]. CSCs are 
highly insensitive to chemotherapy and other kinds of 
treatment, which can lead to inefficient management 
of the disease [16]. One of the factors determining the 
potential survival of stem cells, the possibility of their 
self-renewal and resistance to chemotherapy, is the 
Wnt signalling pathway. It controls the sequence of 
events leading to the neoplastic transformation of co-
lon mucosa. Catalano et al. proved that Wnt-b-catenin 
pathway drives an inverse, coordinated regulation of 
D2 and D3 in CRC cells. Moreover, they demonstrated 
that CR-CSCs are highly sensitive to intracellular T3, 
while D3 maintains CRC stem cells in the undifferenti-
ated status and enhances tumour growth. T3 appears 
effective in inducing cell differentiation, affects the Wnt 
target-related genes, and makes the CR-CSCs more 
sensitive to chemotherapy. The results of the study 
suggest that the effect of chemotherapy on T3-induced 
cells could be superior to the effect chemotherapy on 
normal CRC cells.
Zhu et al. investigated the role of TH receptor b1 
(TRb1) in the progression of CRC [17]. Mutations of 
TRs have already been found to play a role in many 
kinds of cancers (such as breast, thyroid, hepatocellular, 
and renal clear cell cancer) [9, 10, 18, 19]. Additionally, 
mice in which mutated TR gene have been introduced 
develop follicular thyroid cancer with enhanced ca-
pabilities of metastasising to the lungs [20]. Zhu et 
al. analysed 222 tissue samples from patients with 
CRC. Decreased expression of TRb1 mRNA in colon 
and rectum adenocarcinoma samples was found in 
89.7% of samples. Furthermore, the study analysed 
the correlation between TRb1 protein expression and 
clinicopathological characteristics of the CRC cases. It 
Table II. Cell lines studies
First author  
Year of the study
Type of studied 
cells
The aim  
of the study 
Mechanism Outcomes Conclusions
Dentice M. et al. 
2012 [21]
Colon cancer cell 
lines
The role of D3 in 
the regulation of T3 
signalling in cancer 
cells
Absence of D3 
increases level 
of T3 
Higher level of T3 inhibits 
colon cancer cells 
proliferation and promotes 
differentiation in cultured 
cells
Regulation of T3 may 
be targeted to reduce 
the oncogenic effects of 
b-catenin in intestinal cells
Catalano V. et al. 
2015 [13]
Colorectal cancer 
stem cells
Influence of D3 and 
T3 on colorectal 
cancer stem cells
Depletion of 
D3 increases 
intracellular 
thyroid hormone 
concentration
Higher level of T3 induces 
cell differentiation and 
sharply mitigate tumour 
formation
Combined action on 
intracellular T3 and 
chemotherapy could 
improve colorectal cancer 
treatment
Lee Y.-S. et al. 
2018 [22]
Colorectal cancer 
cells
Influence of T4 on 
colorectal cancer 
cells
T4 induces 
nuclear B-catenin 
accumulation, as 
well as high cyclin 
D1 and c-Myc
T4 promotes B-catenin 
activation and cell-
proliferation in colorectal 
cancer
An applicable therapeutic 
strategy including T4 
regulation could be 
considered
Zhu L. et al.  
2016 [17]
Normal colon 
mucosa cells, 
human colorectal 
cancer cells
The role of TRB1 
in the CRC tissues 
and cells 
TRB1 works via the 
PI3K/Akt pathway
TRB1 plays a critical role in 
the progression of CRC 
TRB1 could be a potential 
target for CRC therapeutics
CRC — colorectal cancer
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resulted in a statistically significant (p = 0.045) inverse 
relation between the tumour size and TRb1 expression, 
i.e. the expression was lower in tumours larger than 5 
cm. Moreover, the results showed that overexpression of 
TRb1 inhibits CRC cell proliferation and suppresses the 
migration of the cells by inhibiting PI3K/Akt signalling. 
All the findings could suggest that TRb1 plays an impor-
tant role in CRC progression by regulating PI3K/AKT 
pathway and can be a future target in CRC therapy. 
Another cell line study was conducted by Dentice 
et al. and investigated the role of D3 in the regulation 
of T3 signalling in cancer cells [21]. The study explored 
the correlation between D3 expression in CRC cells and 
B-catenin complex. The results showed that B-catenin 
up-regulation of D3 leads to reduced levels of T3, which 
inhibits differentiation and promotes cellular prolifera-
tion. A higher level of D3 was also found in adenoma-
tous epithelium and CRC. The conclusion of the study 
was that affecting B-catenin-D3-T3 pathway could be 
a potential target for new CRC therapies. 
Only Lee et al. presented results in contrast to those 
described above [22]. Their study investigated the role 
of T4 in CRC cell lines and its effect on B-catenin activa-
tion. According to the study, T4 enhanced cell prolifera-
tion in both CRC cell lines used (HCT 116 and HT-29) 
by hyper-activation of Wnt/B-catenin cascade. Higher 
level of B-catenin was connected with faster progression 
of the disease and unfavourable survival. However, Lee 
et al. pointed out that T4 and T3 may present different 
functions in the progression of CRC, and the relation-
ships between THs require deeper exploration.
Human studies
A total of seven studies on humans were included into 
the analysis. Of those, four analysed only CRC risk and 
three analysed CRC as a subgroup. Five of the seven 
were case-control studies. The remaining two were 
cohort studies. Only one study was prospective. The 
characteristics of the included studies are summarised 
in Table III.
Rennert et al. in a case-control study on 2566 matched 
pairs showed that TH replacement therapy is associ-
ated with lower risk of CRC, with OR = 0.59 (95% 
CI: 0.43–0.82, p = 0.001) [23]. After being adjusted 
for age, sex, use of aspirin and statins, sports activ-
ity, family history of CRC, ethnic group, and level of 
vegetable consumption, the results remained statisti-
cally significant with aOR = 0.60 (95% CI: 0.44–0.081, 
p = 0.001). In accordance with the well-known fact 
that hypothyroidism is much more common in women 
than in men, the study showed that levothyroxine 
supplementation was more frequent in female than 
in male control subjects (8.2% vs. 2.0%, respectively, 
p < 0.0001). While reduction of CRC in men with Ta
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levothyroxine supplementation was not statistically 
significant (OR = 0.75, 95% CI: 0.42–1.36, p = 0.35), 
the association in women was (OR = 0.54, 95% CI: 
0.38–0.75, p < 0.0001). After subgroup analysis, the 
study showed reduced risk of CRC in postmenopausal 
women supplementing levothyroxine (OR = 0.53, 
95% CI: 0.37–0.74, p < 0.001). Furthermore, analysis 
was adjusted for hormone (oestrogen) replacement 
therapy (HRT), and the results showed a statistically 
significant effect among non-HRT users (OR = 0.49, 
95% CI: 0.33–0.74, p < 0.001) but not among HRT us-
ers (OR = 0.90, 95% CI: 0.35–2.36, Pinteraction = 0.19). In 
the fully adjusted model for postmenopausal women, 
levothyroxine supplementation was related with 
significant reduction in CRC risk (OR = 0.60, 95% CI: 
0.4–0.81, p = 0.001). 
As a response to the study by Rennert et al., Fried-
man et al. published data on 12,207 patients with colon 
cancer and 4729 with rectum/rectosigmoid cancer [24]. 
Each patient was matched with 50 controls. Accord-
ing to this study, rectal cancer risk was lower in men 
supplementing levothyroxine for at least five years 
(OR = 0.66, 95% CI: 0.45–0.97, p = 0.03). Risk reduc-
tion of colon cancer was not statistically significant. The 
risks for postmenopausal women, both HRT users and 
non-users, were slightly reduced but not statistically 
significant.
Boursi et al. published data from a nested case-con-
trol study on a large UK population, showing similar 
results [25]. A total of 20,990 CRC patients were matched 
with 82,054 controls. The study focused on determining 
the risk of developing CRC as a result of thyroid dys-
function with TH replacement, as well as without it. Pa-
tients with TH replacement history were included into 
the study. Analysis of CRC risk was stratified by time of 
THs supplementation (0–6 months, 6–12 months, 1–5 
years, 5–10 years, and > 10 years before index data) 
because the process of CRC tumorigenesis is multistep 
and lasts from 10 to 15 years. Adjusted OR for CRC in 
thyroxine-users was 0.88 (95% CI: 0.79–0.99, p = 0.03) 
and 0.68 (95% CI: 0.55–0.83, p<0.001) for treatment initi-
ated 5 to 10 years and more than 10 years before index 
data, respectively. The results were adjusted for age, 
male sex, diabetes mellitus, smoking, alcohol use, and 
NSAID use. The analysis of the association between tim-
ing of TH replacement initiation and CRC risk showed 
that the protective influence is increased with cumula-
tive duration of therapy. Moreover, the patients with 
clinical or subclinical hypothyroidism with no history 
of THR had higher risk of CRC compared to patients 
without any thyroid dysfunction (OR = 1.16, 95% CI: 
1.08–1.24, p < 0.001). Hyperthyroidism was also associ-
ated with an increased CRC risk (OR = 1.21, 95% CI: 
1.08–1.36, p = 0.001). 
A case-control study by Guifang et al. analysed 273 
colorectal neoplasm patients matched with 819 controls 
[26]. The prevalence of subclinical hypothyroidism 
(SCH) was significantly higher in group of patients 
with colorectal neoplasm, compared to those without 
(p < 0.01). Colorectal neoplasms were found in 67 
(34.9%) subjects in the SCH group, which was more 
than that in euthyroid group (206, 24.1%, p = 0.002). 
Moreover, patients with SCH were more likely to have 
advanced colonic lesions and CRC compared with eu-
thyroid subjects (p = 0.028 and p = 0.036, respectively). 
After adjusting for blood pressure, body mass index, 
history of hypertension, and smoking, an association 
still existed between colorectal neoplasm and SCH 
(OR = 1.689, 95% CI: 1.21–2.36, p = 0.002). The authors 
concluded that a strong association between SCH and 
colorectal neoplasm was identified. SCH was found to 
be an independent risk factor for colorectal neoplasm. 
Furthermore, three studies on cancer risk and TH 
imbalance contained data on CRC. A prospective cohort 
study by Chen et al. on 3863 patients reported adjusted 
hazard ratio (HR) of 1.19 (95% CI: 1.00–1.42, p = 0.048) 
of CRC for patients with subclinical hypothyroidism 
(SCH) [27]. Chen et al. in 2013 published data from 
a case-control study on 1521 patients with Hashimoto 
disease (HD) matched with 6084 non-Hashimoto and 
reported adjusted HR of 4.76 of developing CRC (95% 
CI: 1.36–16.6. p < 0.05) [28]. The same authors reported 
data from a longitudinal cohort study on 5025 patients 
with Graves-Basedow disease (GD) matched with 
non-GD patients, which revealed a protective effect 
of this disease on CRC risk with aHR of 0.61 (95% CI: 
0.30–1.24, p < 0.001) [29] 
Discussion
The development of preventive strategies in CRC is 
a subject of extensive research. The relationship be-
tween CRC risk and some widely used medications 
such as metformin or statins has been described and 
showed promising results [5, 6, 30]. Another possible 
factor influencing the development of CRC is an imbal-
ance of thyroid hormones resulting from diseases such 
as: subclinical hypothyroidism, Hashimoto’s disease, 
and Graves-Basedow disease, and their treatment. The 
first report on the protective effects of THs replacement 
therapy on CRC risk was published by Rennert et al. in 
2010 [23]. Further studies were in accordance with those 
results, showing that high concentrations (but within 
range) of THs diminishes the risk of CRC. Despite 
those promising initial results, to date only 11 papers 
analysing this subject are available, both on molecular 
and epidemiological level. Therefore, more thorough 
examination of this subject seems warranted. 
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Cell lines studies 
In vitro studies analysed in our review showed en-
couraging results; however, to date only four papers 
were published. Despite being based on varying 
methodologies, two of four came to similar conclusions, 
suggesting that higher concentrations of T3 achieved 
by inhibition of D3 serve as an inhibitor of tumourigen-
esis. Moreover, one study explored the role of TRb1 in 
cancer progression, which could become a target for 
molecular therapy. Only one study by Lee showed 
unfavourable results, i.e. that T4 promotes cancer 
proliferation. However, T4 is not a biologically active 
form, and therefore these results should be interpreted 
cautiously. All included cell-line studies bear limitations 
of a very specific design, which analyses only certain 
scenarios, such as inhibition of D3. It would be of great 
interest to compare the influence of T3 versus T4 on 
proliferation and differentiation of CRC cell lines and 
CRC CSC, to fully understand the role of TSH-T4-T3 axis 
on CRC development. Additional points of interest are 
the influence of TSH on peripheral cells as well as rT3, 
which contributes to 0.9% of THs in the bloodstream 
[31]. Furthermore, the presented studies analyse the 
influence of inhibition of only one enzyme: D3 deio-
dinase, while there are more enzymes that take part in 
metabolic pathways of T4 and T3, such as deiodinase 
type 1 and 2. Inhibition or activation of those enzymes 
could potentially influence the tumourigenesis of CRC 
and therefore could be a future target for molecular 
therapy. Some existing studies describe in detail the 
relationships and interdependences between THs and 
CRC, but straightforward conclusions on the effects of 
those relationships are lacking. Those conclusions (i.e. 
whether T3 or T4 promote or inhibit carcinogenesis) 
could be an essential foundation for potential animal 
and human studies. In summary, initial in vitro stud-
ies on the influence of THs on CRC show promising 
results. However, further research is needed — both to 
confirm available results and to explore other possible 
associations between the THs axis and CRC. This will 
enable clear conclusions to be drawn, which would be 
the rationale for animal and human studies. 
Animals studies 
The search strategy of this review identified no studies 
conducted on animals, despite the fact that similar sce-
narios were tested with metformin, aspirin, or statins [6, 
32]. Animal studies investigating the effect of metformin 
showed that it reduces aberrant crypt foci formation 
and downregulates tumour angiogenesis. Aspirin has 
been shown to prevent colorectal cancer and CRC 
metastasis in mice. Such studies could contribute to 
the state of knowledge of association of levothyroxine 
supplementation and CRC risk. 
Human studies 
Studies on humans included in this analysis show 
consistent and promising results. Concentrations of 
THs within the upper limit of normal correlate with 
lower risk of CRC in all of the analysed studies. How-
ever, the quality of available data is moderate due to 
retrospective study designs, which are susceptible to 
multiple biases. Moreover, there are numerous factors 
contributing to cancer risk in general and CRC risk 
specifically, such as age, sex, diet, region of residence, 
or medications. On the other hand, epidemiology 
of thyroid diseases is also age- and sex-dependent. 
Therefore, it is essential to perform adjusted analy-
ses of CRC risk that include both typical risk factors 
(such as age and sex) and less typical such as com-
mon medications that are known to influence CRC 
risk, including metformin and aspirin. The included 
studies report adjusted ORs; however, factors in-
cluded into adjustment are varied. Moreover, there 
is a trend towards supplementation of T4 both in 
healthy individuals and in individuals with SCH [33]. 
Therefore, in light of growing use of TH supplements, 
it is essential to explore possible connections between 
level of supplementation and CRC risk. Furthermore, 
existing studies did not analyse dose escalation of 
T4 supplementation and did not report information 
on how the dose was established. This is of great 
interest because dose escalation of other drugs that 
serve a protective role in CRC risk enhanced this ef-
fect. Another interesting aspect of TH replacement is 
the time of exposure. Typically, patients who suffer 
from hypothyroidism are diagnosed in their twen-
ties, while the average age of CRC diagnosis is 60+ 
years old. Therefore, time of exposure is substantially 
longer in comparison to other drugs that may serve 
a protective role in CRC, such as the aforementioned 
metformin or aspirin. 
The main strength of this study is its novelty. This 
is, to our knowledge, the first available systematic 
review on the influence of TH imbalance on CRC. It 
systematically summarises findings on the topic in 
a Cochrane-style manner, which is another important 
quality.
The main limiting factor of the present study is 
the volume of included studies. This is due to scarce 
amounts of series available in the literature. This limits 
the possibilities to draw clear and definitive conclu-
sions, a trend is visible nonetheless. Moreover, some of 
the studies acquired data via questionnaires in a retro-
spective manner and therefore are susceptible to recall 
bias. Most of the studies included into the review were 
case-control studies and therefore were susceptible to 
time window bias, i.e. a bias resulting from measuring 
exposure over unequal time intervals. 
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In conclusion, based on our literature review, there 
is growing evidence suggesting a possible role of eu-
thyreosis in CRC prevention and treatment. Further 
studies are required to validate these results. 
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